The European Commission has approved Opdivo (nivolumab) as a second-line treatment for adults with advanced inoperable, recurrent, or metastatic esophageal squamous cell carcinoma (ESCC), who previously were treated with fluoropyrimidine and platinum chemotherapy agents. This decision follows a positive recommendation by the Committee for Medicinal Products for Human Use (CHMP), a branch of the European Medicines Agency. With this approval, Opdivo is now the first immunotherapy able to treat ESCC patients in Europe. “Today’s approval marks a critically…
You must be logged in to read/download the full post.
The post Opdivo Approved in Europe as Second-line Therapy for Advanced Esophageal Cancer appeared first on BioNewsFeeds.